In the BioHarmony Drug Report Database
Moxetumomab pasudotox
Lumoxiti (moxetumomab pasudotox) is an antibody pharmaceutical. Moxetumomab pasudotox was first approved as Lumoxiti on 2018-09-13. It is used to treat hairy cell leukemia in the USA. The pharmaceutical is active against B-cell receptor CD22.
Trade Name
|
Lumoxiti |
|---|---|
Common Name
|
moxetumomab pasudotox |
ChEMBL ID
|
CHEMBL1743043 |
Indication
|
hairy cell leukemia |
Drug Class
|
Monoclonal antibodies |
Image (chem structure or protein)
